Acorda Therapeutics (NASDAQ:ACOR) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report report published on Friday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Stock Performance

ACOR stock opened at $0.66 on Friday. Acorda Therapeutics has a 12 month low of $0.61 and a 12 month high of $24.20. The firm’s 50-day moving average is $11.75 and its 200 day moving average is $12.36. The company has a quick ratio of 0.26, a current ratio of 0.33 and a debt-to-equity ratio of 3.07.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG purchased a new position in Acorda Therapeutics in the 4th quarter worth about $26,000. Prudential Financial Inc. purchased a new position in Acorda Therapeutics during the 2nd quarter valued at about $28,000. Geode Capital Management LLC increased its position in Acorda Therapeutics by 44.8% during the 4th quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 20,948 shares during the period. Virtu Financial LLC purchased a new position in Acorda Therapeutics during the 2nd quarter valued at about $68,000. Finally, Susquehanna International Group LLP increased its position in Acorda Therapeutics by 1,759.1% during the 1st quarter. Susquehanna International Group LLP now owns 218,830 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 207,059 shares during the period. Hedge funds and other institutional investors own 12.71% of the company’s stock.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.